Literature DB >> 2531605

Concentration-effect relationships and individual responses to doxazosin in essential hypertension.

R Donnelly1, H L Elliott, P A Meredith, J L Reid.   

Abstract

1. This study investigates aspects of the pharmacokinetics, pharmacodynamics and concentration-effect relationships in 10 patients with essential hypertension during acute and chronic treatment with doxazosin, an alpha 1-adrenoceptor antagonist. 2. Following the first dose of doxazosin (2 mg) there were significant reductions in blood pressure, increases in heart rate and in plasma noradrenaline, and parallel rightward shifts of the phenylephrine pressor response curves, consistent with alpha-adrenoceptor antagonism. There was no significant change in the pressor response to angiotensin II. 3. Using an integrated kinetic-dynamic model, individual blood pressure responsiveness was characterised as the fall in blood pressure (mm Hg) per unit drug concentration. Responsiveness to the first dose of doxazosin was directly correlated with the responsiveness after 1 and 6 weeks treatment although there was a systemic reduction (of approximately 30%) which occurred during the first week of treatment. 4. Neither the acute nor long-term responsiveness to doxazosin was related to age, plasma renin activity, plasma noradrenaline or the pretreatment sensitivity to phenylephrine. There was a significant relationship between responsiveness and the height of the initial (pretreatment) blood pressure. 5. Integration of pharmacokinetic and pharmacodynamic data provides a reproducible index of responsiveness which can be used to investigate the consistency of the long-term anti-hypertensive response, to identify factors which influence the magnitude of the response, and to optimise the choice of dose and dose interval.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2531605      PMCID: PMC1380011          DOI: 10.1111/j.1365-2125.1989.tb03537.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  27 in total

1.  Simultaneous radioenzymatic determination of plasma and tissue adrenaline, noradrenaline and dopamine within the femtomole range.

Authors:  M Da Prada
Journal:  Life Sci       Date:  1976-10-15       Impact factor: 5.037

Review 2.  Pharmacokinetic-pharmacodynamic relationships of alpha-adrenoceptor antagonists.

Authors:  R Donnelly; P A Meredith; H L Elliott
Journal:  Clin Pharmacokinet       Date:  1989-10       Impact factor: 6.447

3.  Simplified radioimmunoassay for serum aldosterone utilizing increased antibody specificity.

Authors:  J K McKenzie; J A Clements
Journal:  J Clin Endocrinol Metab       Date:  1974-04       Impact factor: 5.958

4.  Determination of the vasodilator UK33274 by high-performance liquid chromatography using fluorescence detection.

Authors:  P C Rubin; J Brunton; P Meredith
Journal:  J Chromatogr       Date:  1980-11-14

5.  Role of plasma kallikrein in the proteolytic activation of the renin-angiotensin system.

Authors:  F H Derkx; B N Bouma; H L Tan-Tjiong; A J Man in 't Veld; J H de Bruyn; G J Wenting; M A Schalekamp
Journal:  Clin Exp Hypertens       Date:  1980       Impact factor: 1.749

6.  Prediction of response to antihypertensive therapy with prazosin.

Authors:  E P MacCarthy; G W Frost; J C Monaghan; B A Mennie; G S Stokes
Journal:  Med J Aust       Date:  1980-07-26       Impact factor: 7.738

7.  Immediate cardiovascular responses to oral prazosin--effects of concurrent beta-blockers.

Authors:  H L Elliott; K McLean; D J Sumner; P A Meredith; J L Reid
Journal:  Clin Pharmacol Ther       Date:  1981-03       Impact factor: 6.875

8.  Prazosin, pharmacokinetics and concentration effect.

Authors:  D N Bateman; D C Hobbs; T M Twomey; E A Stevens; M D Rawlins
Journal:  Eur J Clin Pharmacol       Date:  1979-09       Impact factor: 2.953

9.  Responsiveness of hypertensive subjects to prazosin.

Authors:  G S Stokes; J C Monaghan; E P MacCarthy; H F Oates
Journal:  Clin Exp Pharmacol Physiol       Date:  1980 Mar-Apr       Impact factor: 2.557

10.  Prazosin kinetics in hypertension.

Authors:  A Grahnén; P Seideman; B Lindström; K Haglund; C von Bahr
Journal:  Clin Pharmacol Ther       Date:  1981-10       Impact factor: 6.875

View more
  8 in total

1.  The description and prediction of antihypertensive drug response: an individualised approach.

Authors:  R Donnelly; P A Meredith; H L Elliott
Journal:  Br J Clin Pharmacol       Date:  1991-06       Impact factor: 4.335

Review 2.  The implications of noncompliance with antihypertensive medication.

Authors:  B Girvin; G D Johnston
Journal:  Drugs       Date:  1996-08       Impact factor: 9.546

3.  Encounter frequency and serum glucose level, blood pressure, and cholesterol level control in patients with diabetes mellitus.

Authors:  Fritha Morrison; Maria Shubina; Alexander Turchin
Journal:  Arch Intern Med       Date:  2011-09-26

Review 4.  Pharmacokinetic-pharmacodynamic relationships of alpha-adrenoceptor antagonists.

Authors:  R Donnelly; P A Meredith; H L Elliott
Journal:  Clin Pharmacokinet       Date:  1989-10       Impact factor: 6.447

Review 5.  Concentration-effect analysis of antihypertensive drug response. Focus on calcium antagonists.

Authors:  R Donnelly; H L Elliott; P A Meredith
Journal:  Clin Pharmacokinet       Date:  1994-06       Impact factor: 6.447

6.  Pharmacokinetic-pharmacodynamic modeling of the antihypertensive effect of eprosartan in Black and White hypertensive patients.

Authors:  Petra C van Rijn-Bikker; Oliver Ackaert; Nelleke Snelder; Reinier M van Hest; Bart A Ploeger; Richard P Koopmans; Ron A A Mathôt
Journal:  Clin Pharmacokinet       Date:  2013-09       Impact factor: 6.447

Review 7.  Doxazosin. An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia.

Authors:  B Fulton; A J Wagstaff; E M Sorkin
Journal:  Drugs       Date:  1995-02       Impact factor: 9.546

Review 8.  Clinical pharmacokinetics of vasodilators. Part II.

Authors:  R Kirsten; K Nelson; D Kirsten; B Heintz
Journal:  Clin Pharmacokinet       Date:  1998-07       Impact factor: 6.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.